-
Posted by
Two Blokes Apr 21 -
Filed in
Stock
-
7 views
uniQure's AMT-130 gene therapy for Huntington's Disease shows promising trial data, leading to significant stock price increases and potential for FDA accelerated approval. QURE's stock has seen volatility but has near-term catalysts like BLA submission and 36-month trial data, suggesting potential for immediate further gains. Despite competition from PTC518, AMT-130's effectiveness and one-time treatment advantage could drive substantial revenue and stock price growth.
